Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial

Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot be used with many medications, and are limited to virus-specific targets.(1–3) Biophysical modeling of SARS-CoV-2 replication predicted that protein translation is an especially attractive target for ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Bramante, Carolyn T, Beckman, Kenneth B, Mehta, Tanvi, Karger, Amy B, Odde, David J, Tignanelli, Christopher J, Buse, John B, Johnson, Darrell M, Watson, Ray H. B., Daniel, Jerry J, Liebovitz, David M, Nicklas, Jacinda M, Cohen, Kenneth, Puskarich, Michael A, Belani, Hrishikesh K, Siegel, Lianne K, Klatt, Nichole R, Anderson, Blake, Hartman, Katrina M, Rao, Via, Hagen, Aubrey A, Patel, Barkha, Fenno, Sarah L, Avula, Nandini, Reddy, Neha V, Erickson, Spencer M, Fricton, Regina D., Lee, Samuel, Griffiths, Gwendolyn, Pullen, Matthew F, Thompson, Jennifer L., Sherwood, Nancy, Murray, Thomas A., Rose, Michael R., Boulware, David R, Huling, Jared D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275003/
https://www.ncbi.nlm.nih.gov/pubmed/37333243
http://dx.doi.org/10.1101/2023.06.06.23290989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275003/
https://www.ncbi.nlm.nih.gov/pubmed/37333243
http://dx.doi.org/10.1101/2023.06.06.23290989

Ejemplares similares